
|Articles|October 17, 2012
Antibody may improve plaque psoriasis
A fully human monoclonal antibody that has been found to inhibit interleukin-17A may significantly improve moderate-to-severe plaque psoriasis, according to new phase 2 study data recently released.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Delgocitinib Advances to Phase 3 Evaluation for Lichen Sclerosus
2
The “6-7” Advances for Dermatologists to Look Forward to in 2026
3
Obagi Launches ALOHA Program to Capture Real-World Insights in Aesthetic Injectables
4
Quoin Targets World’s First Approval for Netherton Syndrome Therapy in Saudi Arabia
5



















